2024
Treatment resistant depression in a young female successfully treated with a combination of ketamine and pramipexole – A case report
Ibrahim W, Yang Y, Matuskey D. Treatment resistant depression in a young female successfully treated with a combination of ketamine and pramipexole – A case report. Psychiatry Research Case Reports 2024, 3: 100228. DOI: 10.1016/j.psycr.2024.100228.Peer-Reviewed Original ResearchTreatment-resistant depressionForced Swim TestResistant depressionAntidepressant medicationAdequate trial of antidepressant medicationClasses of antidepressant medicationsTrials of antidepressant medicationsMesolimbic dopaminergic pathwayPatients' depressive symptomsD2/3 receptorsSwim testMood stabilizersDopaminergic pathwaysElectroconvulsive therapyDepressive symptomsAdequate trialKetamine infusionDopamine deficiencyFailure of treatmentDepressionYoung adult femalesPramipexoleCase reportPreclinical studiesKetamine
2022
The steroidogenic inhibitor finasteride reverses pramipexole-induced alterations in probability discounting
Floris G, Scheggi S, Pes R, Bortolato M. The steroidogenic inhibitor finasteride reverses pramipexole-induced alterations in probability discounting. Brain Research Bulletin 2022, 181: 157-166. PMID: 35122898, PMCID: PMC9012661, DOI: 10.1016/j.brainresbull.2022.01.020.Peer-Reviewed Original ResearchConceptsProbability discountingNucleus accumbensMonoamine-depleting agent reserpinePathological gambling severityImpulse-control disordersEffects of reserpineHighest dose of finasterideRisk of pathological gamblingParkinson's diseaseLever pressPathological gamblingDopamine receptorsGambling severityDoses of finasteridePramipexole treatmentRat's propensityAccumbensPramipexoleRestless legs syndromeImpact of finasterideReceptor upregulationNormalizing effectPD patientsReserpineReceptor expression
2020
The adverse effects of pramipexole on probability discounting are not reversed by acute D2 or D3 receptor antagonism
Orrù M, Strathman H, Floris G, Scheggi S, Levant B, Bortolato M. The adverse effects of pramipexole on probability discounting are not reversed by acute D2 or D3 receptor antagonism. European Neuropsychopharmacology 2020, 32: 104-119. PMID: 31983530, PMCID: PMC9325630, DOI: 10.1016/j.euroneuro.2020.01.005.Peer-Reviewed Original ResearchConceptsEffect of pramipexoleProbability discountingDopamine D<sub>2</sub>Monoamine-depleting agent reserpineD3 receptor antagonismAntagonist L-741,626Impulse-control disordersDopamine receptor agonistsRES-treated ratsSB-277011AAntagonist racloprideCombination of pramipexoleNucleus accumbensL-741,626Behavioral effectsNeurobehavioral mechanismsDopamine receptorsAntagonist GRAcute treatmentPramipexoleReceptor antagonismReceptor agonistsRisk takingDopamineImpulse
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply